TNDM
Tandem Diabetes Care Inc Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$19.11Close
$1.3BMarket cap
$12.82 – $28.2652-week range
Nov 5, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 47 · weaker than 53% of stocks over 12 months
- Far from its high 32% below its 52-week high
- Past its pivot 10.1% above its $17.35 pivot
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
32%
1wk
up 9.6%
price change
1mo
up 17.2%
price change
12-month return
up 31%
market up 11% ·
its own up 15%
F-score
4 / 9
Weak
Altman Z
0.05
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
8.4×
price / book
Earnings yield
down 12.3%
EBIT / enterprise value
Cheaper than
14%
of the market · expensive
Revenue growth
up 8%
year on year
EPS growth
—
latest quarter
Sales growth
up 6%
latest quarter · +0 pts
ROE
down 98%
return on equity
Free cash margin
down 3%
-$29.7M FCF
D/E
2.00
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- profitability slipped from last year
- short-term liquidity weakened
- issued more shares
- profits backed by cash
- reduced long-term debt
- gross margin widened
- assets working harder
Repair signals
- Gross margin 52.1% → 53.8%
Trade setup
ATR%
5.1%
$0.97 a day · 2×ATR $17.16
RS
47 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
0.99
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Contractions
3
35% → 18% → 13%
Pivot
$17.35
10.1% above
Volume dry-up
1.1×
10 vs 50 sessions
Trend template · 3 of 8
- Price above the 150 and 200-day averages: passes
- 150-day average above the 200-day: fails
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: passes
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 3.1% over the year, from 66m to 68m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+14% vs market2 sessions after results
Financials
- Gross 54%
- Net -20%
- Free cash -3%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $498.8M | $702.8M | $801.2M | $747.7M | $940.2M | $1.0B |
| Gross margin | 52% | 54% | 52% | 49% | 52% | 54% |
| Operating income | -$8.0M | $22.7M | -$92.8M | -$233.2M | -$99.1M | -$187.3M |
| Net income | -$34.4M | $15.6M | -$94.6M | -$222.6M | -$96.0M | -$204.7M |
| Net margin | -7% | 2% | -12% | -30% | -10% | -20% |
| Earnings per share | -$0.56 | $0.24 | -$1.47 | -$3.43 | -$1.47 | -$3.04 |
| Free cash flow | -$2.7M | $97.2M | $16.4M | -$58.6M | $5.0M | -$29.7M |
| Free cash margin | -1% | 14% | 2% | -8% | 1% | -3% |
| Cash | $94.6M | $71.2M | $172.5M | $58.9M | $69.2M | $90.6M |
| Long-term debt | — | — | — | $285.0M | $308.3M | $310.0M |
| Shareholders' equity | $366.3M | $433.1M | $439.9M | $313.6M | $263.1M | $155.2M |
| Shares outstanding | 62.34m | 63.83m | 64.51m | 65.55m | 66.26m | 68.29m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 19, 2026 | Annual ↗ | Dec 31, 2025 | 50d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| Apr 30, 2025 | Quarterly ↗ | Mar 31, 2025 | 30d |
| Feb 26, 2025 | Annual ↗ | Dec 31, 2024 | 57d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 21, 2024 | Annual ↗ | Dec 31, 2023 | 52d |
| Nov 1, 2023 | Quarterly ↗ | Sep 30, 2023 | 32d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| May 21, 2026 | Holder rights changed · Director or officer change · Shareholder vote ↗ |
| May 15, 2026 | Director or officer change ↗ |
| May 7, 2026 | Results ↗ |
| Feb 27, 2026 | Material agreement · New obligation · Unregistered share sale · Other events ↗ |
| Feb 19, 2026 | Results ↗ |
| Dec 30, 2025 | Charter or bylaws ↗ |
| Nov 12, 2025 | Director or officer change ↗ |
| Nov 6, 2025 | Results ↗ |
| Aug 7, 2025 | Other events ↗ |
| Aug 6, 2025 | Results ↗ |
| May 23, 2025 | Material agreement · Shareholder vote ↗ |